Economic Burden of Medically Attended Respiratory Syncytial Virus Infections Among Privately Insured Children Under 5 Years of Age in the USA
Influenza and Other Respiratory Viruses · 2024
DOI: 10.1111/irv.13347 ↗Kurz gefasst
Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Phuong T Tran und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Cost of Illness, Health Care Costs, Insurance, Health. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC, Merck.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
The cost of medically attended RSV LRI (lower respiratory infection) is critical in determining the economic value of new RSV immunoprophylaxes. However, most studies have focused on intermittent RSV encounters, not the episode of care that captures the entirety of RSV illness.
Methods
We created age‐ and condition‐specific cohorts of children under 5 years of age using MarketScan® data (2015–2019). We contrasted aggregating healthcare costs over RSV‐LRTI episodes to ascertaining costs based on RSV‐specific encounters only. Economic burden was estimated by multiplying costs per encounter or per episode by their respective incidence rates.
Results
Average cost was higher per episode than per encounter regardless of settings (inpatient: $28,586 vs. $18,056 and outpatient/ED: $2099 vs. $407 for infants). Across ages, the economic burden was highest for infants and RSV‐LRTI requiring inpatient care, but the burden in outpatient/ED settings was disproportionately higher than costs due to higher incidence rates (for inpatient vs. outpatient episodes: $226,403 vs. $101,269; for inpatient vs. outpatient encounters: $151,878 vs. $38,819 per 1000 infant‐years). For high‐risk children, cost and burden were up to 3–10 times higher, respectively.
Conclusions
With a comprehensive stratification by settings and risk condition, the encounter‐ versus episode‐based estimates provide a robust range for policymakers' economic appraisal of new RSV immunoprophylaxes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
- Faculty of Pharmacy, HUTECH University, Ho Chi Minh City, Vietnam.
- Department of Pharmaceutical Systems and Policy, School of Pharmacy, Morgantown, West Virginia, USA.
- West Virginia University Cancer Institute, West Virginia University, Morgantown, West Virginia, USA.
- Center for Drug Evaluation and Safety, University of Florida, Gainesville, Florida, USA.
- Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, Florida, USA.
ORCID-Profile: Phuong T Tran, Yoonyoung Choi, Almut G Winterstein
Förderung
- Merck Sharp & Dohme LLC
- Merck
Zitieren
APA
Tran, P. T., Nduaguba, S. O., Wang, Y., Diaby, V., Finelli, L., Choi, Y., & Winterstein, A. G. (2024). Economic Burden of Medically Attended Respiratory Syncytial Virus Infections Among Privately Insured Children Under 5 Years of Age in the USA. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.13347
Vancouver
Tran PT, Nduaguba SO, Wang Y, Diaby V, Finelli L, Choi Y, et al. Economic Burden of Medically Attended Respiratory Syncytial Virus Infections Among Privately Insured Children Under 5 Years of Age in the USA. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.13347
BibTeX
@article{Tran2024,
author = {Tran, Phuong T and Nduaguba, Sabina O and Wang, Yanning and Diaby, Vakaramoko and Finelli, Lynn and Choi, Yoonyoung and Winterstein, Almut G},
title = {Economic Burden of Medically Attended Respiratory Syncytial Virus Infections Among Privately Insured Children Under 5 Years of Age in the USA},
journal = {Influenza and Other Respiratory Viruses},
year = {2024},
doi = {10.1111/irv.13347}
}
EUVIMED